Skip to main content
v2026.11,986 entries · CC-BY 4.0

PVSF (CASRAI)

Pharmacovigilance Course Online: Drug Safety Foundation, PVSF (CASRAI)

An examined pharmacovigilance course: AE, ADR and SAE terms, valid ICSRs, seriousness and causality, MedDRA, CTCAE and reporting clocks. 50-question exam, 70% pass. US$119.

LevelFoundationPVSPVSF (CASRAI)
3 h
Nominal
Self-paced study
7
Lessons
Self-paced
6
Domains
Exam blueprint
50
Exam items
Per attempt
70%
Pass mark
Fixed, uncurved
90
Retake wait
Days
3 yr
Valid for
From the pass

What you earn

The credential itself

Pass the examination and CASRAI issues this certificate and the post-nominal PVSF (CASRAI), signed by the Programme Director, valid for 3 years, and checkable by anyone from the verification code on its face.

Specimen. Issued as a signed PDF and as a machine-readable Open Badge; the holder and code shown are illustrative.
How it appears on your CV

Certifications

PVSF (CASRAI) — Pharmacovigilance & Drug Safety, Foundation

CASRAI·Issued Mar 2026·Credential ID CASRAI-PVS-2026-IOSGWN

casrai.org/verify/CASRAI-PVS-2026-IOSGWN

Every certificate is issued under the signature of Dr. Diana Nieves Castro, MD, Programme Director of CASRAI Certification, who sets the syllabus, blueprint and pass mark for this credential.

It certifies that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published on this page — and anyone can confirm it from the verification code, without an account and without contacting us.

About this credential

What it covers

Who this course is for

The Pharmacovigilance and Drug Safety Foundation course is for people whose work already touches safety data and who want that knowledge examined: study coordinators, research nurses, investigators, drug-safety associates and case processors early in their careers, clinical data managers, monitors, IRB and ethics committee staff, and medical information staff. It teaches how the safety system works (definitions, case validity, coding, grading and reporting clocks). It does not teach clinical judgement or the medical management of adverse reactions.

What you will be able to do

  • Define adverse event, adverse drug reaction, suspected adverse reaction, serious adverse event and SUSAR, and name the document each definition comes from (ICH E2A, ICH E2D(R1), 21 CFR 312.32).
  • Tell “serious” from “severe”, and apply the seriousness criteria and the important medical event clause to described cases.
  • Decide whether an incoming report meets the four minimum criteria for an individual case safety report (ICSR), find day zero, and classify the report as spontaneous or solicited.
  • Assess seriousness, expectedness and causality as three separate judgements, choose the right reference safety document, and combine the three into a reporting decision.
  • Explain the MedDRA hierarchy, multi-axiality and the primary SOC, read a CTCAE grade correctly, and spot a missing dictionary or grading-scale version in a protocol.
  • State the expedited reporting clocks under ICH E2A, 21 CFR 312.32, 21 CFR 314.80 and EU GVP Module VI, say which jurisdiction each comes from and who must receive the report.
  • Contrast trial and post-marketing safety work, and explain why spontaneous reporting data support signal detection but cannot estimate incidence.

The modules

  1. The vocabulary of safety. The core definitions read from the source texts, serious versus severe, the life-threatening note, important medical events, and why “side effect” is no longer used.
  2. From a report to a case. The four minimum criteria, patient and reporter identifiability, day zero, spontaneous and solicited reports, follow-up, narratives and duplicates.
  3. The three axes: serious, unexpected, related. Reference safety information, the specificity and severity rule, who may judge causality, and how the three judgements combine.
  4. Coding and grading. MedDRA levels, multi-axiality, the primary SOC and Standardised MedDRA Queries; CTCAE grades and why a grade is not a seriousness decision; version control.
  5. Clocks and destinations. The 7- and 15-day clocks for trials, US IND safety reports and 15-day Alert reports, the EU 15- and 90-day time frames, blinded cases, and IRB or ethics committee reporting as a separate duty.
  6. The safety landscape. Trial versus post-marketing safety, the main reporting systems (FDA’s adverse event reporting systems, VAERS, EudraVigilance, the MHRA Yellow Card scheme and WHO’s VigiBase), the limits of spontaneous data, the GVP modules, and signals and risk management plans at awareness level.
  7. Consolidation and practice exam. A review of the most common errors and a practice exam that is not scored toward the credential.

The exam

  • 50 scored multiple-choice questions per attempt, each with four options, drawn from a larger question bank in proportion to the domain weights below. Options are shuffled for every attempt.
  • Pass mark: 70%.
  • You must finish the exam within 4 hours of starting it.
  • You must complete all lessons before you can start the exam.
  • If you do not pass, you can retake the exam after 90 days.

Domain weights: safety vocabulary 22%; from a report to a valid case 18%; seriousness, expectedness and causality 20%; coding and grading 16%; expedited reporting 14%; the pharmacovigilance landscape 10%.

Eligibility

Foundation: there is no experience or education prerequisite.

Professional (PVSP), for comparison: candidates qualify through one of three routes: 24 months’ full-time-equivalent experience in a pharmacovigilance, drug-safety or clinical-safety role within the last six years; a degree or diploma in medicine, pharmacy, nursing, life sciences, public health, epidemiology or a related field plus 12 months of such experience; or PVSF (CASRAI) in good standing plus 12 months of such experience. Professional candidates confirm at checkout that they meet one of these routes; no documents are checked at purchase.

What the credential is, and what it is not

Passing the exam earns PVSF (CASRAI), an examined credential issued by CASRAI that anyone can verify. It shows that you passed an exam on the content above.

  • It is not accredited by any accreditation body.
  • It carries no CE, CME or CEU credit.
  • It does not satisfy any statutory, regulatory, funder, sponsor or institutional training requirement.
  • It is not endorsed by ICH, FDA, EMA, MHRA, the MedDRA MSSO, NCI or any other regulator, funder or professional body.
  • It does not make anyone eligible to act as a Qualified Person Responsible for Pharmacovigilance (QPPV), and it confers no authority to make clinical decisions.

Validity and renewal

PVSF (CASRAI) is valid for three years from the date you pass. To renew, you pass the current version of the exam again.

Price and access

US$119, paid once. Course access does not expire.

Body of knowledge

Exam blueprint

The exam is assembled to these weights on every attempt. They are published before purchase because a blueprint you cannot see is not a blueprint.

Domains and weights6 domains · 50 scored items
DomainWeight
Safety vocabulary and its precisionF1
22%11 items
From a report to a valid case (the ICSR)F2
18%9 items
Seriousness, expectedness and causalityF3
20%10 items
Coding and grading: MedDRA and CTCAEF4
16%8 items
Expedited reporting: clocks and destinationsF5
14%7 items
The pharmacovigilance landscapeF6
10%5 items
Total100%

Every attempt has this many items from each domain. The items themselves are drawn at random from the bank within those fixed per-domain quotas, so no two attempts are the same paper.

Syllabus

Syllabus: 7 lessons, 3 hours

Every lesson and every learning outcome is listed. The lesson bodies open on enrolment, and the exam opens once every lesson is marked complete.

7 lessons · 3.3 h

Lesson material opens once you are enrolled. The full syllabus and every learning outcome are shown here so you can judge the coverage before you pay.

  1. Lesson 1

    Module 1

    1 lesson · 30 min

    1. Locked.The vocabulary of safety30 min · Locked

      On completion you will be able to

      • Define adverse event, adverse drug reaction, suspected adverse reaction, serious adverse event and SUSAR, and cite the source document for each (E2A, E2D(R1), 21 CFR 312.32(a)).
      • Classify a described occurrence as an adverse event, an adverse drug reaction or neither, and state the reason.
      • Apply the seriousness criteria and the important medical event clause to a described case and name the criterion that applies.
      • Distinguish 'serious' from 'severe' in a given case and explain why only seriousness drives regulatory reporting.
      • Identify imprecise or deprecated terms (such as 'side effect') in a safety narrative and replace them with the correct term.
  2. Lesson 2

    Module 2

    1 lesson · 30 min

    1. Locked.From a report to a case30 min · Locked

      On completion you will be able to

      • Decide whether an incoming report meets the four minimum criteria for an ICSR, and name the criterion that is missing when it does not.
      • Identify day zero for a described intake involving staff, contractors or partners.
      • Classify a report as spontaneous or solicited (including patient support programmes) and state what the classification changes.
      • Specify the follow-up needed for an incomplete report and state when follow-up starts a new reporting clock.
      • Explain why duplicate detection is a safety activity, using the causes of duplicates listed in E2D(R1).
  3. Lesson 3

    Module 3

    1 lesson · 30 min

    1. Locked.The three axes: serious, unexpected, related30 min · Locked

      On completion you will be able to

      • Assess seriousness, expectedness and causality as three independent judgements for a described case.
      • Select the correct reference safety document for an expectedness assessment in a trial and in post-approval use.
      • Apply the specificity and severity rule to decide whether a reported event is unexpected.
      • Explain why a sponsor's disagreement with a reporter's causality assessment does not remove reportability.
      • Combine the three judgements to reach a reporting decision and state which rule triggered it.
  4. Lesson 4

    Module 4

    1 lesson · 30 min

    1. Locked.Coding and grading: MedDRA and CTCAE30 min · Locked

      On completion you will be able to

      • Name the five MedDRA levels in order and state which level provides maximum specificity.
      • Explain multi-axiality and what the primary SOC assignment prevents, using an example term.
      • Choose between MedDRA and CTCAE for a stated purpose, and choose an SMQ for a retrieval task.
      • Read a CTCAE grade correctly and explain, for a given case, why the grade does not decide seriousness.
      • Identify a missing or mismatched MedDRA or CTCAE version in a protocol or data set and state the consequence.
  5. Lesson 5

    Module 5

    1 lesson · 30 min

    1. Locked.Clocks and destinations30 min · Locked

      On completion you will be able to

      • Determine whether a described case qualifies for expedited reporting under E2A, 21 CFR 312.32, 21 CFR 314.80 or GVP Module VI.
      • State the applicable deadline for a case, the event that starts the clock, and the jurisdiction the rule comes from.
      • List every party that must receive a given report, including participating investigators for US IND safety reports.
      • Distinguish a regulatory clock from a protocol clock and from an IRB/IEC reporting requirement in a described scenario.
      • Explain how a blinded serious case is handled for expedited reporting under E2A III.D.
  6. Lesson 6

    Module 6

    1 lesson · 15 min

    1. Locked.The safety landscape: trials, post-marketing and reporting systems15 min · Locked

      On completion you will be able to

      • Contrast trial and post-marketing safety work on reference document, population, denominator, causality default and reporting framework.
      • Name the main spontaneous reporting systems (FDA's systems, VAERS, EudraVigilance, Yellow Card, VigiBase) and state who runs each and what it covers.
      • Explain, for a described use of spontaneous report counts, why the data cannot support an incidence estimate.
      • Describe at awareness level what a signal is and what a risk management plan contains.
      • Locate a GVP module from its topic and explain why Modules XI-XIV are void.
  7. Lesson 7

    Module 7

    1 lesson · 30 min

    1. Locked.Consolidation and practice exam30 min · Locked

      On completion you will be able to

      • Correct each of the ten most common safety-reporting errors in a described case.
      • Work a described case end to end: validity, the three axes, jurisdiction, deadline and recipients.
      • Complete an untimed practice exam and identify their weakest domain from the results.
      • Describe the format and rules of the scored exam.

Assessment

How the exam works

The exam is closed-book and multiple choice. Each attempt draws a fresh form to the domain weights above, so no two attempts are the same paper and no answer key circulates. The pass mark is 70% and is fixed — there is no curve, no quota and no adjustment by cohort.

Scoring is immediate. Pass, and every item is reviewed with the option you chose, the correct option and its rationale. If you do not pass, you see your overall score and your score per domain (smaller domains are grouped together); which items you missed, and their answers, are held back so your resit is still a real assessment. A failed attempt may be retaken after 90 days. The wait exists so a retake is a second attempt at the material rather than a second attempt at remembering the paper.

The exam opens once you have marked every lesson of the course complete. Forms are assembled to the blueprint above or not at all: where a domain cannot yet be sampled to that standard, the exam declines to start rather than issue an unbalanced paper. Your material and progress are never affected, and there is no time limit on when you sit.

Passing candidates are issued a certificate with a verification code, valid for 3 years from the date of the pass. Anyone can check that code on our public verification page without an account and without contacting us. To renew, pass the current examination again: renewal opens 180 days before the certificate expires, and a pass issues a renewed certificate valid for a further 3 years from that date.

Certifying authority

Signed by Dr. Diana Nieves Castro, MD

CASRAI’s certification programme is academically and medically directed by Dr. Diana Nieves Castro, MD, Programme Director, who sets the syllabus and blueprint for this credential and signs every certificate issued under it.

CASRAI has maintained the terminology and reporting standards of research administration for over a decade. It assumed leadership of the CRediT contributor-roles taxonomy in 2014 and carried it through to adoption as ANSI/NISO Z39.104-2022, now in use by publishers, funders and institutions worldwide. This examination is drawn from that body of work.

What the credential certifies: that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published above. It is valid for 3 years, and anyone can check it from the verification code on its face.

The ladder

Other levels of Pharmacovigilance & Drug Safety

Levels are independent purchases. There is no prerequisite chain — sit whichever level matches the work you already do.

All CASRAI credentials

Common questions

Pharmacovigilance Course Online: Drug Safety Foundation, PVSF (CASRAI): common questions

How much does a pharmacovigilance course cost?

The CASRAI Pharmacovigilance & Drug Safety Foundation course costs US$119, a one-time payment by card through Stripe checkout. Course access does not expire, and the exam for the PVSF (CASRAI) credential is included.

What is the syllabus for a pharmacovigilance course?

The Foundation course has seven lessons: the vocabulary of safety; from a report to a case; the three axes (serious, unexpected, related); coding and grading with MedDRA and CTCAE; clocks and destinations; the safety landscape of trials, post-marketing and reporting systems; and a consolidation lesson with a practice exam. The exam is weighted across six domains, from safety vocabulary (22%) to the pharmacovigilance landscape (10%).

How to get into pharmacovigilance training?

The Foundation tier has no experience prerequisite, so you can start it without a prior safety role. It is written for people whose work already touches safety data, such as study coordinators, research nurses, drug-safety associates and case processors early in their careers, data managers, monitors and IRB staff. It teaches how the safety system works (definitions, case validity, coding and reporting clocks), not clinical judgement.

Can I get free online courses with certificates?

This course is not free: it costs US$119, paid once, because it ends in an examined credential rather than a completion certificate. The exam has 50 multiple-choice questions with four options each, the pass mark is 70%, and it opens once all lessons are complete. Each PVSF (CASRAI) certificate has a public verification page and is valid for three years.

How long does the pharmacovigilance course take?

The course has seven lessons with 3 hours of study. The online exam must be completed within 4 hours of starting it. If you do not pass, you can retake it after a 90-day waiting period.

What are the two types of pharmacovigilance?

Safety work is usually split into pre-approval safety in clinical trials and post-approval safety for marketed products, and each has its own reporting rules. The Foundation course contrasts the two and covers how reports are classified by source, such as spontaneous versus solicited reports.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →